Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis

Meng, Min; Gao, Bei; Wang, Xia; Zhang, Bai; Sa, Rina; Ge, Bin

doi:10.1186/s12872-016-0206-6

Cited by 9 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of in-stent thrombosis (ST) and SVG occlusions was similar at 5 years with 1st generation DES like the paclitaxel eluting stent (PES) in the SYNTAX trial [56] . Advancements of stent technology, with the development of everolimus eluting stent (EES), have provided improvements in immediate 1-year ST rate (0.60% vs. 1.59%) [57] and 5-year ST rate (1.30% vs. 1.86%) [16] when compared to first-generation DES. However, as ST exerts a greater effect on mortality than SVG occlusion [56] , ischemia-driven target lesion revascularization (ID-TLR) may be a more apt comparison with SVG graft failure.…”

Section: Desmentioning

confidence: 99%

“…The 2-stage approach encompasses an interval of 1-2 days between surgical and endovascular CAR [71] . It allows for control of bleeding in the post-operative period before initiation of anti-platelet therapy and does 1 Drug eluting stent occlusion was measured by rates of target lesion revascularization; 2 saphenous vein graft patency was measured by angiographic evidence of vessel occlusion; 3 1-year data from a meta-analysis comparing 1st generation DES (PES and SES) to 2nd generation DES (EES) [57] ; 4 5-year data from a meta-analysis comparing 1st generation DES (PES) to 2nd generation DES (EES) [16] ; 5 1-…”

Section: Conventional Hcrmentioning

confidence: 99%

“…The indications, benefits and shortcomings of surgical and endovascular CAR are evolving and a constant source of debate [6,13] . However, two aspects of CAR are overwhelmingly agreed on: the left internal mammary artery (LIMA) is the longest-lasting and most event free conduit for CABG and the completeness of CAR is an important determinant of its long-term outcome [14][15][16] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Respite for hybrid coronary revascularization

Gacad¹,

Singh²,

Motwani³

et al. 2019

View full text Add to dashboard Cite

Hybrid coronary revascularization incorporates a surgical anastomosis of the left internal mammary artery to the left anterior descending coronary artery through a thoracotomy and percutaneous implantation of drug eluting stents in diseased non-left anterior descending coronary arteries. Hybrid coronary artery revascularization can be performed as a 1-stage procedure in a hybrid operating room or as a tightly scheduled 2-stage procedure. Hybrid coronary artery revascularization is seldom the selected modality for coronary revascularization due to the lack of a hybrid operating room in many hospitals, the recommended thoracotomy approach for bypass, or the rigid schedule of surgical and endovascular revascularization. A 2-stage approach, using a sternotomy as compared to standard thoracotomy, and a flexible schedule between surgical and endovascular procedures may facilitate the adoption of hybrid coronary revascularization with noncomplex multi-vessel stable coronary artery disease.

show abstract

Section: Desmentioning

confidence: 99%

Section: Conventional Hcrmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Respite for hybrid coronary revascularization

Gacad¹,

Singh²,

Motwani³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The second-generation DES, with thinner cobalt chromium alloy material and symmetric coating made by better biocompatible polymers loaded superior drugs such as everolimus and zotarolimus, has better safety and efficacy that can significantly reduce the rate of myocardial infarction and cardiovascular death 11 . However, there is no significant difference in the incidence of late or very late stent thrombosis 12 . 4 The challenge of third-generation stent is to overcome delayed endothelialization, late or very late stent thrombosis and other clinical issues.…”

Section: Introductionmentioning

confidence: 96%

An asymmetrical dual coating on the stent prepared by ultrasonic atomization

et al. 2018

View full text Add to dashboard Cite

This study aims to design an asymmetric dual coating (ADC) on the stent by ultrasonic atomization to solve the problem of delayed endothelialization and late or very late stent thrombosis which caused by drug eluting stent (DES) with symmetric coating. Chitosan loaded monoclonal platelet glycoprotein IIIa receptor antibody SZ-21 coating (CSC) was sprayed on inner surface of stents, and outer surface was sprayed CSC and poly(lactic-co-glycolic acid) (PLGA) loaded with docetaxel (DTX) coating (PDC). The coated surface was uniform without aggregation and no shedding phenomenon either before or after stent expanded. Fluorescence labeling has confirmed that the coating has an asymmetric structure. The cumulative release for SZ-21 and DTX was 40.11 % and 27.22 % within first 24 h, then DTX became the major released drug from 24 h to 7 d, after released for 28 d about 40% of the SZ-21 and 50% DTX still remained on the coated stent. It achieved that ADC can inhibit thrombosis at earlier period and inhibit vascular smooth muscle cells (VSMCs) proliferation at later period. And that ADC has good hemocompatibility and can significantly inhibit VSMCs proliferation. Finally, 4 and 12 weeks after the stent with ADC implanted into rabbit carotid arteries, it showed that the stent with ADC was safe and could effectively prevent thrombosis and in-stent restenosis.

show abstract

“… 1 In addition, due to the aging of the population and the accelerated process of urbanization, the prevalence of cardiovascular disease risk factors is increasing year by year, which leads to an increasing number of cardiovascular diseases. 2 – 4 According to some research reports, cardiovascular disease is the leading cause of death among urban and rural residents in China. 5 – 7 Coronary heart disease (CHD) is one of the most common cardiovascular diseases, and its mortality has also been on the rise in recent years.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial

Lü

et al. 2018

DDDT

View full text Add to dashboard Cite

BackgroundPrevious studies have indicated that nicorandil can reduce perioperative myocardial injury (PMI) in patients undergoing elective percutaneous coronary intervention (ePCI), but this conclusion is still controversial. Additionally, studies reporting on the safety of nicorandil are lacking. Therefore, we performed this prospective study to evaluate the efficacy and safety of nicorandil on PMI in patients undergoing ePCI.MethodsOne hundred and forty-six patients with coronary heart disease (CHD) scheduled to undergo ePCI were randomly assigned to the nicorandil group (n=74) or control group (n=72). The primary outcomes were the change in cardiac troponin T (cTnT) and creatine kinase-MB (CK-MB) at 12 and 24 hours after surgery. The secondary outcome was the incidence of major adverse cardiac events (MACE), which was a composite of cardiac death, nonfatal myocardial infarction, new heart failure or coronary revascularization.ResultsThere was no difference in age (54.76±5.93 vs 56.35±5.22) between the nicorandil group and the control group. In addition, no differences were observed in the cTnT and CK-MB levels between the two groups at admission (all P⩾0.05). Compared with those in the control group, the cTnT (0.15±0.12 vs 0.12±0.10 at 12 hours and 0.17±0.12 vs 0.13±0.10 at 24 hours) and CK-MB (15.35±8.23 vs 12.31±7.93 at 12 hours and 13.63±8.87 vs 11.13±5.71 at 24 hours) levels in the nicorandil group were significantly decreased after surgery (all P⩽0.05). Furthermore, nicorandil did not increase the incidence of MACE in the nicorandil group compared with the control group (12.16% vs 12.50%).ConclusionsNicorandil can reduce PMI in patients undergoing ePCI and does not increase the incidence of MACE.Clinical Trial RegistrationURL: http://www.chictr.org.cn/. Unique Identifier: ChiCTR-IOR-17012056.

show abstract

Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis

Cited by 9 publications

References 52 publications

Respite for hybrid coronary revascularization

Respite for hybrid coronary revascularization

An asymmetrical dual coating on the stent prepared by ultrasonic atomization

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial

Contact Info

Product

Resources

About